Drug interactions
Ipratropium-salbutamol + Octreotide
Severity: Moderate
Ipratropium-salbutamol and Octreotide: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Octreotide can cause bradycardia and QT prolongation, and salbutamol may add to QT effects at high doses. The combined risk is generally small but relevant in patients with cardiac disease or electrolyte disturbance.
What this interaction means in plain words
Ipratropium-salbutamol and Octreotide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Ipratropium-salbutamol belongs to Respiratory; Octreotide belongs to Endocrine.
Why it happens
Additive QT prolongation, with salbutamol-induced hypokalemia as a possible contributor.
What to do
Monitor ECG and electrolytes in patients with additional QT risk factors. Correct hypokalemia before starting or increasing therapy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ipratropium-salbutamol and Octreotide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ipratropium-salbutamol
Other interactions of Octreotide
Frequently asked questions
Can I take Ipratropium-salbutamol with Octreotide?
MediHelp rates the interaction as moderate. Ipratropium-salbutamol and Octreotide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Octreotide can cause bradycardia and QT prolongation, and salbutamol may add to QT effects at high doses. The combined risk is generally small but relevant in patients with cardiac disease or electrolyte disturbance.
How serious is the interaction between Ipratropium-salbutamol and Octreotide?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor ECG and electrolytes in patients with additional QT risk factors. Correct hypokalemia before starting or increasing therapy.
What other medicines interact with Ipratropium-salbutamol?
MediHelp also lists interactions of Ipratropium-salbutamol with, for example, Amisulpride, Arsenic trioxide, Carvedilol. The full list is on the Ipratropium-salbutamol page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
